IOL Chemicals & Pharmaceuticals Ltd

Q1 FY27Pharmaceuticals & Biotechnology

IOL Chemicals & Pharmaceuticals Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book

Q1 FY27 earnings call: what management guided on revenue, margins and order book.

Price₹194

Market cap₹5.9K Cr

P/E33.2

Published11 Sept 2026

What the Q1 FY27 call signalled

2 of 4 strong

RevenueRank 3

MarginRank 3

CapexYes

Order bookYes

Not discussed on this call: fundraise.

The short version

For FY27, the company expects revenue growth of 15% to 20% with EBITDA margin between 14% to 15% (Page 5, 9). FY27 revenue growth guidance: 15% to 20%; EBITDA margin forecasted at 14% to 15%.

From IOL Chemicals & Pharmaceuticals Ltd's Q1 FY27 earnings-call transcript · updated 11 Sept 2026.

Revenue & Sales Performance

Rank 3

For FY27, the company expects revenue growth of 15% to 20% with EBITDA margin between 14% to 15% (Page 5, 9).
Growth is driven by higher capacity utilization, better product mix, operational efficiencies, and strong demand in domestic and export markets (Page 9).
For FY28, a similar growth rate of 15% to 20% in top line and 15% to 17% EBITDA margin is targeted, subject to market conditions (Page 9).
Sustainable growth is supported by a diversified and broad-based product portfolio expanding beyond ibuprofen (Page 7, 13).
Export contribution is targeted around 25% to 30% of revenue, with potential to move toward 30%+ (Pages 4, 15).
Capacity expansions and backward integration initiatives combined with R&D efforts aim to strengthen future growth (Pages 12, 15).
The company anticipates the non-ibuprofen segment to contribute around 50%-55% to pharma revenue by FY29, helping further growth (Page 9).

Profitability & Margins

- FY27 revenue growth guidance: 15% to 20%; EBITDA margin forecasted at 14% to 15%. - Q1 FY27 EBITDA margin at 14.6%, indicating potential to sustain margin above guidance. - FY28 expected revenue growth: 15% to 20%; EBITDA margin target: 15% to 17%, subject to prevailing market conditions. - Broad-based growth expected across product portfolio, especially from non-ibuprofen products contributing significantly to pharma revenue. - Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. - Export revenue targeted around 25%-30%, with potential upside. - Continued emphasis on operational efficiencies, better capacity utilization, and product mix improvements driving profitability. - Expect non-ibuprofen API segment to contribute 50%-55% of pharma revenue by FY29 with margins comparable to ibuprofen. Overall, the company projects sustainable, steady growth with improving margins and robust export potential over the coming years.

See what IOL Chemicals & Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Yes

IOL plans a capex of approximately INR 200-250 crores annually, with around 60% directed toward expansion and new product development, and 40% toward infrastructure and efficiency improvements.
The company has a 101-acre land parcel for future expansion, with statutory permissions underway.
Major new projects on this land are not expected to be commissioned within the current fiscal year (FY27); likely FY28 or FY29 growth platforms.
IOL is actively working on R&D initiatives, with investments in advanced analytical equipment (XRD, LCMS, GCMS) to support product development.
The company is exploring backward integration opportunities but will share updates after proof-of-concept within R&D pipelines.
The capital allocation approach remains disciplined, focusing on projects offering attractive long-term returns.

Fundraising & Capital Structure

There is no specific mention of any current or planned fundraising through debt or equity in the transcript provided.
The company discussed ongoing capex plans of around INR 200-250 crores annually, with 60% directed towards expansion and new products and 40% for infrastructure and efficiency improvements.
Expansion plans include acquiring statutory permissions for a 101-acre land parcel, with no major projects expected on this land within the current fiscal year.
Management indicated a cautious approach to financial guidance without explicitly mentioning new funding rounds.
Any future capex or growth projects may be funded from internal accruals or existing resources, as there is no explicit statement on raising fresh debt or equity.

See what IOL Chemicals & Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Yes

IOL Chemicals and Pharmaceuticals Limited has reasonable visibility into their order book for the coming quarter as of Q1 FY27.
The company expects sustained demand based on this order book visibility, supporting their confident revenue growth guidance.
They anticipate revenue growth of around 15% to 20% with EBITDA margins around 14% to 15% for FY27, indicating a healthy order inflow.
The management did not provide specific quantitative details on the size of the order book but emphasized strong demand in domestic and export markets.
Capacity utilization improvements and operational efficiencies suggest ongoing and likely increasing order fulfillment.
Export customers have agreed quantities under contracts, though quarterly export numbers may fluctuate based on shipment timings, reflecting ongoing order commitments.

How does IOL Chemicals & Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisIOL Chemicals & Pharmaceuticals Ltd

Rev 3Mar 3

See where IOL Chemicals & Pharmaceuticals Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

IOL Chemicals & Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹619 Cr, net profit ₹53 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What IOL Chemicals's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Innova Captab (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Glenmark Pharma. (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Strides Pharma (Q1 FY27)
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…
Ind-Swift Labs. (Q1 FY27)
Capex of ₹250 crore planned over 2-2.5 years to enhance capacity and build warehouse, supporting growth (Page 14). Key concall takeaways from Ind-Swift…

Compare:vs Sun Pharmaceutical Industries Ltd vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were IOL Chemicals & Pharmaceuticals Ltd Q1 FY27 results?

For FY27, the company expects revenue growth of 15% to 20% with EBITDA margin between 14% to 15% (Page 5, 9). FY27 revenue growth guidance: 15% to 20%; EBITDA margin forecasted at 14% to 15%.

What is IOL Chemicals & Pharmaceuticals Ltd share price analysis?

IOL Chemicals & Pharmaceuticals Ltd currently shows a below-average growth signal. The stock trades at a P/E of 33.2 with a market cap of ₹5,869 Cr. Investors should review the full earnings analysis for detailed insights.

Is IOL Chemicals & Pharmaceuticals Ltd planning capital expenditure?

IOL plans a capex of approximately INR 200-250 crores annually, with around 60% directed toward expansion and new product development, and 40% toward infrastructure and efficiency improvements.

Keep IOL Chemicals & Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.